← Back to Screener

IMVT Report

08-04-2026 | Analyze. Execute. Alpha.

Performance Framework

Earning
Sentiment
Estimate
Short interest
Cdrs
Ta analysis (short term)
Ta analysis (long term)
Insiders action
Institutional conviction
Mf

Key Metrics & Valuation

Market Cap 5.06B$
Next Earning Release 2026-06-04 00:00:00 (NA days)
Correlation to Market 30.0%
Technical Trend Trending up
Current Ratio 15.7
Return on Equity -65.8%
PEG Ratio -0.1
EV/EBITDA -8.4
EV/Revenue 0.0
EV/FCF -9.6
Price to Earning Correlation 74.8%
Total R&D (5yr % of Rev) 0.0%
Institutional Holding 7816.0%

Earnings & Cash Flow

  • This quarter EPS is 19.7% related to same quarter last year.
  • Annual earning is -45.2% compared to last year.
  • Annual average earning surprise in the last 5 years is 0.0%.
  • Earnings in the last 5 years, is trending down .
  • 1.0 of the last 4 quarters had positive surprise.

EBITDA

  • This quarter EBITDA is 4.6% related to same quarter last year.
  • Annual EBITDA in the last 5 years, is trending down.

Free Cash Flow (FCF)

  • This quarter FCF is -29.9% related to same quarter last year.
  • Free cash flow in the last 4 quarters, is trending down .

Revenue/Income

Revenue

  • This quarter revenue is 0.0% related to same quarter last year.

Net Income

  • This quarter income is 0.4% related to same quarter last year.
  • Income ratio in the last 4 quarters, is trending down .
  • Net income ratio in the last 5 years, is trending down .

Sentiment

News Sentiment

  • Short term: 0.0% positive, 0.0% negative.
  • Long term: 65.1% positive, 34.9% negative.

Short Interest

  • Short ratio (Days to cover): 15.9
  • Short as % of float: 18.6%
  • Float share amount is trending up.

Future Estimates

Revenue 0.0%
Net Income 4.8%
EPS 4.8%
Price Target Up Side 56.1%

Company Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Next earning release is on 2026-06-04 00:00:00, in NA days

Technical Analysis

Hourly Momentum

Daily Framework

Weekly Strategic

Interactive Chart

Additional Resources

  • Premium Analysis Locked
  • AI Analyst Reasoning


    Content Locked Premium Analysis Locked (Contact for Access)